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lymphangiogenesis
Gilda Varricchi1,2,3, Stefania Loffredo1,2,3,
Maria Rosaria Galdiero1,2,3, Giancarlo Marone4,5,
Leonardo Cristinziano1,2, Francescopaolo Granata1,2,3 and
Gianni Marone1,2,3,6Angiogenesis and lymphangiogenesis are distinct and
complex processes requiring a finely tuned balance between
stimulatory and inhibitory signals. During adulthood,
angiogenesis and lymphangiogenesis are activated at sites
of tumor growth, tissue injury and remodeling, and chronic
inflammation. Vascular endothelial growth factors (VEGFs),
angiopoietin (ANGPTs) and a multitude of additional
signaling molecules play distinct roles in the modulation of
angiogenesis/lymphangiogenesis. VEGFs and ANGPTs
activate specific tyrosine kinase receptor (e.g., VEGFR1,
VEGFR-2, VEGFR-3 and TIE2 respectively), expressed on
blood endothelial cells (angiogenesis) and lymphatic
endothelial cells (lymphangiogenesis). Although tumor cells
produce VEGFs and other proangiogenic mediators, tissue
resident (e.g., macrophages, mast cells) and circulating
immune cells (e.g., basophils, neutrophils, monocytes,
eosinophils) are an important source of angiogenic/
lymphangiogenic mediators in inflammation and in tumor
microenvironment and at site of chronic inflammation.
Certain immune cells can also release anti-angiogenic
factors. Mast cells, basophils, neutrophils and presumably
other immune cells are not only a source of angiogenic/
lymphangiogenic molecules, but also their target. Cells of the
immune system need consideration as major players and
possible targets for therapeutic manipulation of
angiogenesis/lymphangiogenesis in chronic inflammatory
disorders and tumors.Addresses
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Angiogenesis and lymphangiogenesis are distinct and
complex processes requiring a finely tuned balance
between stimulatory and inhibitory signals [1,2,3].
Analogous to blood vessels, the formation of new lym-
phatic vessels occurs vigorously during embryogenesis,
but is restricted in adults [1]. During adulthood, angio-
genesis/lymphangiogenesis is limited to sites of chronic
inflammation [4], tissue injury or remodeling [5], and
cancer [6].
Angiogenesis is initiated by activation of vascular endo-
thelial growth factor receptor 2 (VEGFR2, a tyrosine
kinase (TK) receptor expressed on blood endothelial cells
(BECs), by soluble vascular endothelial growth factor-A
(VEGF-A)). Although cancer cells are an important
source of VEGF-A and other pro-angiogenic mediators
[7–9], immune cells in tumor microenvironment (TME)
increase VEGF-A availability during the angiogenic
switch [10]. Angiogenesis requires the participation of
additional signaling molecules, including angiopoietin 2
(ANGPT2) and delta ligand-like4 (DLL4), which respec-
tively, destabilizes endothelial cells (EC) junctions and
controls the tip-cell phenotype [11].
VEGFs and their endothelial TK receptors are
central regulators of vasculogenesis, angiogenesis, andwww.sciencedirect.com
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VEGFR2 is the major angiogenic pathway, and blockage
of VEGF-A/VEGFR2 signaling is the major antiangio-
genic strategy [13]. VEGF-C and VEGF-D, through the
engagement of VEGFR3 on lymphatic endothelial cells
(LECs) induce lymphangiogenesis in tumors and stimu-
late the formation of metastasis [14,15].
The vascular endothelial growth factor family
and their receptors
The VEGF family includes VEGF-A, VEGF-B, VEGF-
C, VEGF-D, and placenta growth factor (PlGF) [10].
VEGFs bind with different specificity to three mainly
endothelial transmembrane receptors, VEGFR-1,
VEGFR-2, and VEFGR-3 [16,17,18]. All VEGFRs
have a series of immunoglobulin-like domains in the
extracellular part and an intracellular split TK domain
[12]. Neuropilins 1 (NRP1) and 2 (NRP2) function as co-
receptors for specific VEGFs [3]. VEGF-A signaling
through VEGFR2 activates angiogenesis by inducing
the survival, proliferation, sprouting and migration of
BECs, increases endothelial permeability [19,20]
and induces inflammation [16,21,22].
There are several splicing isoforms of VEGF-A (121, 165,
189, and 206) which differ in their binding to matrix and
to co-receptors; for example, VEGF-A121 is acidic and
freely diffusible whereas VEGF-A165, VEGF-A189, and
VEGF-A206 are basic and bind to heparin and heparin
proteoglycans on cellular surfaces and extracellular matri-
ces [23]. VEGF-A binding to VEGFR2 causes receptor
dimerization and autophosphorylation at several TK resi-
dues [24]. Activation of the receptor leads to its internali-
zation, degradation in the lysosomes or through the
proteasome pathway. These are mechanisms for
VEGFR2 signal downregulation and the rapid turnover
of VEGF-A/VEGFR2 is important for the tight control of
VEGFR signaling [17].
VEGF-A is primarily known for its essential role in
physiologic and pathologic angiogenesis [25] and also
retains lymphangiogenic properties [26]. The angiogenic
activity of VEGF-A is mediated by interaction with
VEGFR2, whereas the lymphangiogenic activity is pro-
moted by binding to VEGFR2/VEGFR3 heterodimer
receptor [12]. VEGF-A stimulates lymphangiogenesis
also indirectly by recruiting immune cells (e.g., macro-
phages, mast cells) that produce VEGF-C and VEGF-D
[21,27]
PlGF is expressed in the placenta, heart and lungs and has
four isoforms (PlGF1–4) [28,29]. VEGF-B is highly
expressed in heart, skeletal muscle and brown fat in
adults and has two major isoforms in humans: VEGF-
B167 binds to heparin proteoglycans, whereas VEGF-B186
does not bind heparin and is more soluble [30]. PlGF and
VEGF-B bind with high affinity to VEGFR1 whose TKwww.sciencedirect.comactivity is weak and downstream signaling poorly under-
stood [17]. VEGFR1 is expressed on ECs, some immune
cells and pericytes, and its TK activity is required for cell
migration towards VEGFs or PlGF [16,22,31]. VEGF-B
and PlGF have been shown to be angiogenic in certain
pathophysiological settings [32]. VEGF-B can modulate
coronary vessel growth and cardiac hypertrophy and lipid
metabolism [29,33].
The VEGF-C/VEGFR3 signaling pathway is the main
pathway implicated in lymphangiogenesis [18]. VEGF-C
is produced as a precursor protein, which is activated by
intracellular convertase [34]. The secreted disulfide-
linked VEGF-C subunit only binds VEGFR3, but the
factor is further proteolysed in the extracellular environ-
ment by proteases to generate homodimeric proteins with
high affinity for both VEGFR2 and VEGFR3 [35].
VEGF-C is crucial for the survival, proliferation, and
migration of LECs [36]. VEGF-D also binds VEGFR3
to promote lymphangiogenesis.Maturation of VEGF-D is
similar to that of VEGF-C and occurs by the cleavage of
N- and C- terminal regions. VEGF-D overexpression
correlates with lymphatic vessels growth and lymphatic
metastasis [37]. VEGFR3, expressed on LECs, is acti-
vated by both VEGF-C and VEGF-D [14]. The role of
VEGFR2 in lymphangiogenesis is still not completely
clarified. VEGFR2 is expressed in LEC at low levels, but
VEGF-A overexpression in skin and in models of wound
healing and skin tumors cause lymphatic vessels hyper-
plasia [38,39].
Angiopoietins (ANGPTs) play an important role in mod-
ulating angiogenesis and lymphangiogenesis. The
ANGPT/Tie system consists of two cell-surface TK
receptors (TIE1 and TIE2) and two ligands ANGPT1
and ANGPT2. TIE2 is primarily expressed on ECs and
binds both ANGPTs, whereas TIE1 is an orphan receptor
that canmodulate TIE2 activity. ANGPT1 and ANGPT2
bind TIE2 on ECs, but elicit different responses.
ANGPT1 is expressed by perivascular cells, such as
pericytes and sustains EC survival of blood endothelial
cells. By contrast, ANGPT2, secreted by ECs, acts auto-
crinally and paracrinally as TIE2 ligand to promote
angiogenesis and lymphangiogenesis [40].
Several chemokines, produced by immune and non-
immune cells, play an important role in the modulation
of angiogenesis and anti-angiogenesis [41]. These mole-
cules are also involved in the recruitment of tumor
infiltrating immune cells [42].
Inflammatory angiogenesis and
lymphangiogenesis
The association between angiogenesis and tumor growth
attracted paramount interest during the last decades for
the obvious implications of the nature of initiation of
tumors and the possibility to inhibit cancer growth byCurrent Opinion in Immunology 2018, 53:152–160
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associated angiogenesis and lymphangiogenesis was a
rather neglected field until recently. The interest in
inflammatory angiogenesis/lymphangiogenesis increased
exponentially during last years for a number of reasons.
First, chronic low grade inflammation is an essential
hallmark of cancer [43]. Second, angiogenesis and lym-
phangiogenesis are components of several inflammatory
disorders [10,44]. Third, there is compelling evidence
that several immune cells can be involved, directly and
indirectly, in the modulation of angiogenesis and lym-
phangiogenesis [4,8,10,16,19,21,27,41,44]. The
latter observation led to the recognition that the interac-
tions between immune cells and the vascular system are
involved in a multitude of human inflammatory diseases
in addition to cancer [45]. Moreover, accumulating evi-
dence suggests that inflammation-associated angiogene-
sis/lymphangiogenesis is not merely an endpoint pheno-
type of inflammation, but rather a dynamic reaction that
can alter the process of inflammatory tissue repair and
resolution [4]. Finally, there is evidence that circulating
progenitor cells can be incorporated into the growing
lymphatic vessels and trans-differentiate into LECs
[4,46].
Human innate effector cells modulate
angiogenesis and lymphangiogenesis
In 1971, Judah Folkman, the father of angiogenic research
suggested that tumor growth is angiogenesis-dependent
and inhibition of angiogenesis could be of therapeutic
value [47]. He also suggested that immune cells, in
particular macrophages and mast cells, could be a source
of angiogenic factors modulating tumor growth. There is
now compelling evidence that several cells of innate and
adaptive immune system can play major roles in the
complex processes of inflammatory and tumor angiogen-
esis/lymphangiogenesis [2,45].
Monocytes
Transcriptomic, epigenetic, and functional studies have
delineated three mononuclear cell lineages within mye-
loid network: monocytes, macrophages, and dendritic
cells [48]. In the past it was assumed that monocytes
merely constitute a transient precursor for tissue macro-
phages. Classical dendritic cells and macrophages origi-
nate independently of monocyte input. Conversely,
monocytes have emerged as a highly plastic and dynamic
cellular system. There are currently three main human
monocyte subpopulations defined as CD14+ CD16+ (clas-
sical monocytes), CD14+ CD16+ (intermediate), and
CD14 CD16+ (non-classical monocytes) [49].
Several stimuli (e.g., M-CSF, ATP, cysteinyl-leukotriene
D4) can stimulate VEGF production from human mono-
cytes [50–52]. These cells are also a target of angiogenic
mediators. Human monocytes express VEGFR1 whose
activation by VEGF-A induce migration [22]. VEGF-A-Current Opinion in Immunology 2018, 53:152–160induced chemotaxis of CD16+ monocytes is reduced
compared to CD16 monocytes due to a lower VEGFR1
expression [53].
De Palma and collaborators have identified a unique
subset of human monocytes which express the TIE2
receptor [54]. TIE2-expressing monocytes are angio-
genic and lymphangiogenic and have been associated
with different human tumors [55,56]. Moreover,
ANGPT2 stimulates TIE2-expressing monocytes to sup-
press T cell activation [57] and it has been shown that
targeting the ANGT2/TIE2 axis inhibits tumor growth
[58].
Macrophages
Macrophages play a pivotal role in chronic inflammation
and tumor growth [59]. These cells are the predominant
immune cells in inflamed tissues as well as in various solid
tumors where they are referred to as tumor-associated
macrophages (TAMs) [60]. Macrophages can promote
tumor progression either directly, by stimulating the
proliferation of cancer cells, or indirectly, by producing
angiogenic and lymphangiogenic factors [61]. These pro-
grams are induced by TAMs in TME by signals resulting
from metabolic conditions (e.g., hypoxia), low pH or from
mediators (e.g., cytokines, LPS, adenosine) in TME
[10,61].
Macrophages purified from human lung parenchyma
(HLMs) activated by secreted phospholipases A2 (sPLA2)
[27] and lipopolysaccaride (LPS) expressed VEGF-A,
VEGF-B, VEGF-C, and VEGF-D at both RNA and
protein levels [62]. Adenosine induced a synergistic
increase of VEGF-A released from HLMs through the
engagement of A2a and A3 receptors [27
]. These results
demonstrate that human tissue resident macrophages can
be a source of both proangiogenic and lymphangiogenic
factors. Interestingly, HLMs express the cannabinoid
receptors types 1 and 2 (CB1 and CB2 receptors) and
the activation of these receptors by specific agonists
inhibits LPS-induced production of VEGF-A, VEGF-
C, ANGPT1 and ANGPT2. The latter findings suggest
that activation of cannabinoid receptors on tissue resident
macrophages may be a novel strategy to modulate vascu-
lar remodeling in cancer and chronic inflammation.
There is increasing evidence of the heterogeneity of the
origin of monocytes and monocyte-derived macrophages
in rodents and in humans [63]. Interestingly, human
monocyte-derived macrophages produce VEGF-A and
VEGF-C, but the release is not modified by the CB1
and CB2 agonists [62]. Macrophage-derived proteases
including matrix metalloproteinases (MMPs) (e.g.,
MMP2, MMP9, MMP12) and serine or cysteine protei-
nases, such as cathepsins and plasminogen activator,
facilitate the infiltrative growth of tumor cells in the
TME [64,65].www.sciencedirect.com
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Mast cells are tissue-resident immune cells, and their
involvement in tumor angiogenesis has long been dem-
onstrated [8,44]. Tissue mast cells and peripheral blood
basophils are the only cells expressing the high-affinity
receptors (FceRI) for IgE and synthesizing a plethora of
pro-inflammatory and immuno-regulatory factors.
Although these cells share some similarities, they play
different roles in several aspects of innate and adaptive
immunity [66].
Several immunologic and non-immunologic stimuli (e.g.,
anti-IgE, PGE2, substance P, corticotropin-releasing hor-
mone, adenosine) induce the production of VEGF-A from
human mast cells (HMCs) [67–69]. We have demon-
strated that human lung mast cells (HLMCs) constitu-
tively express several isoforms of VEGF-A (121, 165, 189,
and 206) and that the IgE-mediated activation of these
cells can induce the release of VEGF-A [21]. In addition
to VEGF-A, HMCs express the two canonical isoforms of
VEGF-B (167 and 186). Importantly, supernatants of
immunologically activated HLMCs induced an angio-
genic response in the chick embryo-chorioallantoic mem-
brane (CAM). Interestingly, HLMCs expressed lym-
phangiogenic factors, such as VEGF-C and VEGF-D
and adenosine increased VEGF-A, and VEGF-C produc-
tion. Both VEGFR1 and VEGFR2 are expressed on
HMCs and VEGF-A, VEGF-B, VEGF-C and VEGF-D
induce mast cell chemotaxis in vitro [21] and in vivo [7]
through the activation of both VEGFR1 and VEGFR2.
Collectively, these results indicate that HMCs are a major
source of both angiogenic and lymphangiogenic factors.
Moreover, VEGFs produced at sites of inflammation and
tumors can amplify mast cell infiltration by interacting
with VEGFRs. Mast cell-derived proteases, such as tryp-
tase, MMP2 and MMP9 chymase, can modulate angio-
genesis [66]. Mast cells can reduce the efficacy of anti-
angiogenic therapy by releasing granzyme B [70]. It
remains to be investigated whether human mast cells
from different anatomic sites and subpopulations of these
cells also express anti-angiogenic molecules when
exposed to immunological stimuli.
Basophils
Basophils purified from peripheral blood of healthy
donors constitutively express mRNA for three isoforms
of VEGF-A (121, 165 and 189) and two isoforms of
VEGF-B (167 and 186) [16]. In addition, basophils
infiltrating human nasal polyps contained VEGF-A stored
in secretory granules. IgE-mediated activation of baso-
phils induced the rapid release of VEGF-A. Human
basophils also express on their surface VEGFR2 and
the co-receptors NRP1 and NRP2. VEGF-A induces
basophil chemotaxis through the engagement of
VEGFR2. These results can have relevance in inflamma-
tory disorders [10,44] and in certain tumors [71] in which
basophils can infiltrate the site of chronic inflammationwww.sciencedirect.comand TME. In contrast to mast cells, basophils do not
express/release lymphangiogenic factors. An interesting
cross-talk between HMCs and basophils is mediated by
the ANGPT1/TIE2 system. ANGPT1 is present in cyto-
plasmic vesicles of human basophils and their activation
rapidly release ANGPT1 that induce HMC chemotaxis
through the activation of TIE2 on their surface [72].
Although basophils can play a role in tumor growth
[8,66] and have been detected in draining lymph nodes
of cancer patients [71], the production of lymphangio-
genic factors by these cells should be further evaluated.
Neutrophils
Neutrophils (PMNs) are abundant granulocytes in human
blood and account for a substantial proportion of immune
cells in TME in experimental and human tumors [61,73].
Because of their terminally differentiated phenotype and
short-half life, the role of neutrophils in tumor develop-
ment has been erroneously considered marginal. Recent
evidence indicates that tumor-associated neutrophils
(TAN) can exert anti-tumoral as well as pro-tumoral
functions and PMNs display unsuspected plasticity
[74]. Human PMNs release VEGF-A in response to
various stimuli (e.g., fMLF, LPS) [75]. We found that
several sPLA2 induce the release of pro-angiogenic mole-
cules such as VEGF-A, CXCL8/IL-8 and ANGPT1
[19]. Interestingly, sPLA2 induced the secretion of
the anti-angiogenic VEGF-A isoform, namely VEGF-
A165b. While the release of VEGF-A, CXCL8/IL-8, and
ANGPT1 was mediated by sPLA2 enzymatic activity
and/or binding to a cell membrane receptor(s), the release
of VEGF-A165b required the interaction with b integrins.
These results suggest that the engagement of different
receptors on human PMNs results in the release of
different isoforms of VEGF-A exerting opposite effects
(e.g., proangiogenic vs antiangiogenic). The translational
relevance of these findings is supported by the observa-
tion that sPLAs are increased in human cancer [76] that
are infiltrated by PMNs [73]. There is no evidence that
human the activation of PMNs induces the production of
lymphangiogenic factors. Neutrophil-derived MMP9
prompts the angiogenic switch in TME [77].
Eosinophils
Eosinophils represent a minor granulocytic cell infiltrate
in experimental and human tumors and have been erro-
neously neglected for decades. Immunologists and
Oncologists are now appreciating the role of these cells
in experimental and human tumors [78,79]. Eosinophils
are present in TME of several human solid and hemato-
logic tumors [78] and their infiltration depends on a
combination of cytokines/chemokines produced by
tumors and by tumor-infiltrating immune cells. Human
eosinophils produce several angiogenic factors such as
VEGF-A [80,81], fibroblast growth factors (FGF-2)
[82,83], CXCL8/IL-8 [84], and osteopontin [85]. Human
eosinophils also produce MMP9 [86–88]. EosinophilsCurrent Opinion in Immunology 2018, 53:152–160
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Several cells of innate and adaptive immune system play a role in the complex process of inflammatory and tumor angiogenesis and
lymphangiogenesis. Activation of human peripheral blood neutrophils, basophils, eosinophils and monocytes induce the production of VEGF-A,
which is the main proangiogenic factor. This molecule signals through the engagement of VEGFR2 on blood endothelial cells (BECs). VEGF-A also
has pro-lymphangiogenic properties by binding to VEGFR2/VEGFR3 heterodimer receptor on lymphatic endothelial cells (LECs). By contrast,
tissue resident macrophages and mast cells produce both proangiogenic (VEGF-A) and lymphangiogenic factors (VEGF-C and VEGF-D). The
lymphangiogenic activity of VEGF-C and VEGF-D is mediated by binding to VEGFR3 on LECs. Neutropilins (NRP1 and NRP2) function as co-
receptors and amplify the tyrosine kinase activity of VEGFRs.have been detected in metastatic lymph nodes of cancer
patients, but the production of lymphangiogenic factors
by these cells should be further addressed.
Concluding remarks and perspectives
Compelling evidence indicates that cells of innate and
adaptive immune system can participate in the complex
processes of inflammatory angiogenesis and lymphangio-
genesis by releasing a wide spectrum of factors which
varies enormously among the various cells. Neutrophils,
basophils, monocytes and eosinophils isolated from
peripheral blood of healthy donors are a major source
of several isoforms of proangiogenic molecules. By con-
trast, macrophages and mast cells isolated from human
tissues produce both angiogenic and lymphangiogenicCurrent Opinion in Immunology 2018, 53:152–160factors (Figure 1). A growing list of immunologic and
non-immunologic stimuli present at sites of inflammation
and in TME activate in vitro cells of innate immunity to
produce angiogenic/lymphangiogenic molecules. How-
ever, a note of caution should be mentioned because
studies in vitro are performed in physiological conditions
which are different from the hostile environment at sites
of inflammation and tumor growth (e.g., low pH, high
concentration of adenosine and oxygen radicals). All the
above factors can profoundly influence the metabolic
activities of immune cells.
Mast cells, basophils, neutrophils, monocytes and pre-
sumably other immune cells are not only a source of
angiogenic/lymphangiogenic molecules, but also a targetwww.sciencedirect.com
Immune cells in angiogenesis Varricchi et al. 157[16,21,22]. In fact, HMCs and basophils express spe-
cific receptors (VEGFR1, VEGFR2 and TIE2) and co-
receptors (NRP1 andNRP2) for angiogenic and lymphan-
giogenic factors. These mediators can also exert pro-
inflammatory effects (e.g., chemotaxis) by engaging
receptors and co-receptors present on HMCs, basophils
and presumably other immune cells. Thus, it is likely that
angiogenic/lymphangiogenic mediators produced by
immune cells at site of inflammation or in TME can
contribute to chronic inflammation and cancer growth by
recruiting further immune cells.
Human basophils, mast cells, macrophages, and PMNs
are among the few cells that express both isoforms of
VEGF-B [16,19,21,27]. Although VEGF-B can
modulate coronary vessels growth [33,89] and lipid
metabolism [90], it remains the most mysterious member
of the VEGF family [91]. We have found that VEGF-B
can play a role in inflammation by inducing immune cells
chemotaxis [16,21]. After being neglected for years, the
role of VEGF-B in inflammation and immunity deserves
further investigations.
Angiogenesis and lymphangiogenesis are controlled by a
delicate balance between a plethora of stimulating and
inhibitory factors which are incompletely understood. We
have found that the engagement of different receptors on
human neutrophils can produce distinct isoforms of
VEGF-A exerting pro-angiogenic and anti-angiogenic
activity [19]. It will be important to verify whether
the activation of subpopulations of PMNs (e.g., N1 vs
N2) leads to the preferential production of pro-angiogenic
or anti-angiogenic molecules. Moreover, additional stud-
ies are urgently needed to identify the release of anti-
angiogenic factors from other human immune cells acti-
vated by different stimuli.
TAM phenotypes are highly plastic, and recent reports
suggest that the canonical model distinguishing polarized
anti-tumor M1 and alternatively polarized pro-tumor M2
incompletely accounts for the phenotypic diversity in vivo
[92]. In addition, there is evidence, at least in rodents, of
subpopulations of N1 and N2 neutrophils [74]. Recent
advances in single-cell genomics technologies are begin-
ning to allow us the identification of a wide spectrum of
TAM and T cell phenotypes [92]. The characterization of
different phenotypes of cells of the adaptive and innate
immune system will reveal subpopulations of immune
cells producing distinct patterns of pro-angiogenic and
anti-angiogenic/lymphangiogenic molecules.
Recent studies have shown that tumor regression or
refractoriness after immune checkpoint blockade (ICB)
with monoclonal antibodies targeting cytotoxic T lym-
phocytes associated antigen 4 (CTLA-4) or programmed
cell-death protein 1 (PD-1) were associated with altered
serum levels of ANGPT2 [93]. Moreover, ICB activateswww.sciencedirect.comCD4+ T lymphocytes which favor tumor blood vessel
normalization [94]. Thus, tumor response to immunother-
apy may involve immune-mediated anti-angiogenic
mechanisms. Cells of the immune system and their
mediators need consideration for future therapeutic
manipulation of angiogenesis/lymphangiogenesis in
chronic inflammatory disorders and tumors.
Conflict of interest statement
Nothing declared.
Acknowledgements
We regret that, because of space limitations, we could not always
adequately quote the work of our colleagues who have greatly contributed
to the field reviewed here. This work was supported in part by grants from
Regione Campania CISI-Lab Project, CRe`ME Project, and TIMING
Project. The authors thank Dr. Gjada Criscuolo for critical reading of the
manuscript and Fabrizio Fiorbianco for the elaboration of the figure.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1.

Zheng W, Aspelund A, Alitalo K: Lymphangiogenic factors,
mechanisms, and applications. J Clin Invest 2014, 124:878-887.
This comprehensive review summarizes the recent progress on lymphan-
giogenic factors and mechanism and their applications in disease
treatment.
2.

Marone G, Granata F: Angiogenesis, lymphangiogenesis and
clinical implications. Preface. Chem Immunol Allergy 2014,
99:XI-XII.
See annotation to Ref. [1].
3. Zachary I: Neuropilins: role in signalling, angiogenesis and
disease. Chem Immunol Allergy 2014, 99:37-70.
4. Kim H, Kataru RP, Koh GY: Inflammation-associated
lymphangiogenesis: a double-edged sword? JClin Invest 2014,
124:936-942.
5. Lee SJ, Park C, Lee JY, Kim S, Kwon PJ, Kim W, Jeon YH, Lee E,
Yoon YS: Generation of pure lymphatic endothelial cells from
human pluripotent stem cells and their therapeutic effects on
wound repair. Sci Rep 2015, 5:11019.
6.

Karaman S, Detmar M:Mechanisms of lymphatic metastasis. J
Clin Invest 2014, 124:922-928.
This elegant review illustrates the complex role of lymphatic vessel and
lymphangiogenic factors in tumor growth and immune modulation in
tumor microenvironment.
7. Melillo RM, Guarino V, Avilla E, Galdiero MR, Prevete N, Rossi FW,
Basolo F, Ugolini C, de Paulis A, Santoro M: Mast cells play a
protumorigenic role in human thyroid cancer. Oncogene 2010,
29:6203.
8. Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R,
Granata F: Are mast cells MASTers in cancer? Front Immunol
2017, 8:424.
9. Prevete N, Liotti F, Visciano C, Marone G, Melillo RM, de Paulis A:
The formyl peptide receptor 1 exerts a tumor suppressor
function in human gastric cancer by inhibiting angiogenesis.
Oncogene 2015, 34:3826-3838.
10.

Varricchi G, Granata F, Loffredo S, Genovese A, Marone G:
Angiogenesis and lymphangiogenesis in inflammatory skin
disorders. J Am Acad Dermatol 2015, 73:144-153.
In this review, the authors discuss the role of cells of innate and adaptive
immunity in the modulation of angiogenesis and lymphangiogenesis in
skin disorders.Current Opinion in Immunology 2018, 53:152–160
158 Lymphangiogenesis: heterogeneity and function11. Potente M, Gerhardt H, Carmeliet P: Basic and therapeutic
aspects of angiogenesis. Cell 2011, 146:873-887.
12. Simons M, Gordon E, Claesson-Welsh L: Mechanisms and
regulation of endothelial VEGF receptor signalling.Nat RevMol
Cell Biol 2016, 17:611-625.
13. Welti J, Loges S, Dimmeler S, Carmeliet P: Recent molecular
discoveries in angiogenesis and antiangiogenic therapies in
cancer. J Clin Invest 2013, 123:3190-3200.
14. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S,
Jaattela M, Alitalo K: Vascular endothelial growth factor C
promotes tumor lymphangiogenesis and intralymphatic tumor
growth. Cancer Res 2001, 61:1786-1790.
15. Achen MG, Williams RA, Baldwin ME, Lai P, Roufail S, Alitalo K,
Stacker SA: The angiogenic and lymphangiogenic factor
vascular endothelial growth factor-D exhibits a paracrine
mode of action in cancer. Growth Factors 2002, 20:99-107.
16.

de Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S,
Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A et al.:
Expression and functions of the vascular endothelial growth
factors and their receptors in human basophils. J Immunol
2006, 177:7322-7331.
This is the first demonstration that human basophils could play a role in
angiogenesis and inflammation through the expression of several forms
of VEGF and their receptors.
17.

Shibuya M, Claesson-Welsh L: Signal transduction by VEGF
receptors in regulation of angiogenesis and
lymphangiogenesis. Exp Cell Res 2006, 312:549-560.
This review illustrates the signal transduction by VEGFR in regulation of
blood endothelial cells and lymphatic endothelial cells.
18. Heinolainen K, Karaman S, D’Amico G, Tammela T, Sormunen R,
Eklund L, Alitalo K, Zarkada G: VEGFR3 modulates vascular
permeability by controlling VEGF/VEGFR2 signaling. Circ Res
2017, 120:1414-1425.
19.

Loffredo S, Borriello F, Iannone R, Ferrara AL, Galdiero MR,
Gigantino V, Esposito P, Varricchi G, Lambeau G, Cassatella MA,
Granata F, Marone G: Group V secreted phospholipase A2
induces the release of proangiogenic and antiangiogenic
factors by human neutrophils. Front Immunol 2017, 8:443.
This is the first demonstration that human neutrophils activated by
different stimuli can release pro-angiogenic and anti-angiogenic factors.
20.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS,
Dvorak HF: Tumor cells secrete a vascular permeability factor
that promotes accumulation of ascites fluid. Science 1983,
219:983-985.
This is the first and elegant identification and characterization of vascular
permeability factor (VPF), now defined as VEGF.
21.

Detoraki A, Staiano RI, Granata F, Giannattasio G, Prevete N, de
Paulis A, Ribatti D, Genovese A, Triggiani M, Marone G: Vascular
endothelial growth factors synthesized by human lung mast
cells exert angiogenic effects. J Allergy Clin Immunol 2009,
123:1142-1149 1149 e1–5.
This report demonstrates that human mast cells are both a source and a
target of angiogenic and lymphangiogenic factors and thereforemay play a
role in inflammatory and neoplastic angiogenesis and lymphangiogenesis.
22. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D:
Migration of human monocytes in response to vascular
endothelial growth factor (VEGF) is mediated via the VEGF
receptor flt-1. Blood 1996, 87:3336-3343.
23. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual
regulation of vascular endothelial growth factor bioavailability
by genetic and proteolytic mechanisms. J Biol Chem 1992,
267:26031-26037.
24. Dougher M, Terman BI: Autophosphorylation of KDR in the
kinase domain is required for maximal VEGF-stimulated
kinase activity and receptor internalization. Oncogene 1999,
18:1619-1627.
25. Carmeliet P: Angiogenesis in life, disease and medicine. Nature
2005, 438:932-936.
26. Wuest TR, Carr DJ: VEGF-A expression by HSV-1-infected cells
drives corneal lymphangiogenesis. J Exp Med 2010,
207:101-115.Current Opinion in Immunology 2018, 53:152–16027.

Granata F, Frattini A, Loffredo S, Staiano RI, Petraroli A, Ribatti D,
Oslund R, Gelb MH, Lambeau G, Marone G, Triggiani M:
Production of vascular endothelial growth factors from human
lung macrophages induced by group IIA and group X secreted
phospholipases A2. J Immunol 2010, 184:5232-5241.
This is the first demonstration that secretes phospholipases A2 can
induce the production of both angiogenic and lymphangiogenic factors
from humanmacrophages suggesting that secreted phospholipases may
play a role in inflammatory and neoplastic angiogenesis and
lymphangiogenesis.
28. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG:
Isolation of a human placenta cDNA coding for a protein
related to the vascular permeability factor. Proc Natl Acad Sci U
S A 1991, 88:9267-9271.
29. Bry M, Kivela R, Leppanen VM, Alitalo K: Vascular endothelial
growth factor-B in physiology and disease. Physiol Rev 2014,
94:779-794.
30. Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O,
Alitalo K, Del Vecchio S, Lei KJ, Chou JY, Persico MG: Two
alternative mRNAs coding for the angiogenic factor, placenta
growth factor (PlGF), are transcribed from a single gene of
chromosome 14. Oncogene 1993, 8:925-931.
31. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J,
Risau W: The vascular endothelial growth factor receptor Flt-1
mediates biological activities. Implications for a functional
role of placenta growth factor in monocyte activation and
chemotaxis. J Biol Chem 1996, 271:17629-17634.
32. Fischer C, Mazzone M, Jonckx B, Carmeliet P: FLT1 and its
ligands VEGFB and PlGF: drug targets for anti-angiogenic
therapy? Nat Rev Cancer 2008, 8:942-956.
33. Karpanen T, Bry M, Ollila HM, Seppanen-Laakso T, Liimatta E,
Leskinen H, Kivela R, Helkamaa T, Merentie M, Jeltsch M et al.:
Overexpression of vascular endothelial growth factor-B in
mouse heart alters cardiac lipid metabolism and induces
myocardial hypertrophy. Circ Res 2008, 103:1018-1026.
34. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E,
Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial
growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and
KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996,
15:1751.
35. Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in
development and human disease. Nature 2005, 438:946-953.
36. Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J,
Norrmen C, Oike Y, Pajusola K, Thurston G, Suda T, Yla-
Herttuala S, Alitalo K: Angiopoietin-1 promotes lymphatic
sprouting and hyperplasia. Blood 2005, 105:4642-4648.
37. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA,
Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG: VEGF-D
promotes the metastatic spread of tumor cells via the
lymphatics. Nat Med 2001, 7:186-191.
38. WirzeniusM, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G,
Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K:
Distinct vascular endothelial growth factor signals for
lymphatic vessel enlargement and sprouting. J Exp Med 2007,
204:1431-1440.
39. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF,
Detmar M: VEGF-A induces tumor and sentinel lymph node
lymphangiogenesis and promotes lymphaticmetastasis. J Exp
Med 2005, 201:1089-1099.
40.

Eklund L, Saharinen P: Angiopoietin signaling in the
vasculature. Exp Cell Res 2013, 319:1271-1280.
In this review, the authors illustrate the current understanding and the
signaling functions of the angiopoietin–Tie pathway and its potential
future development of targeted vascular therapies.
41.

Bosisio D, Salvi V, Gagliostro V, Sozzani S: Angiogenic and
antiangiogenic chemokines. Chem Immunol Allergy 2014,
99:89-104.
Elegant review highlighting that chemokines can exert both pro-genic and
angiogenic roles either by acting directly on endothelial cells or by
recruiting that, in turn, secreted angiogenic mediators.www.sciencedirect.com
Immune cells in angiogenesis Varricchi et al. 15942.

Schulz O, Hammerschmidt SI, Moschovakis GL, Forster R:
Chemokines and chemokine receptors in lymphoid tissue
dynamics. Annu Rev Immunol 2016, 34:203-242.
In this review, the authors focus on the rule of the chemokines and
chemokine receptors in the migration dynamics of immune cells in
infectious and inflammatory processes.
43.

Hanahan D, Weinberg RA: Hallmarks of cancer: the next
generation. Cell 2011, 144:646-674.
In this seminal review, the authors illustrate the fundamental hallmarks of
cancer that provide a framework for understanding the remarkable
diversity of neoplastic diseases.
44. Marone G, Varricchi G, Loffredo S, Granata F: Mast cells and
basophils in inflammatory and tumor angiogenesis and
lymphangiogenesis. Eur J Pharmacol 2016, 778:146-151.
45.

De Palma M, Biziato D, Petrova TV: Microenvironmental
regulation of tumour angiogenesis. Nat Rev Cancer 2017,
17:457-474.
This review illustrates the complex regulation of angiogenesis by the
tumor microenvironment, highlighting potential targets of anti-angiogenic
cancer therapies.
46. Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K,
Bartel G, Krober SM,Greinix H, Rosenmaier A, Karlhofer F,Wick N,
Mazal PR: Lymphatic endothelial progenitor cells contribute to
de novo lymphangiogenesis in human renal transplants. Nat
Med 2006, 12:230-234.
47. Folkman J: Tumor angiogenesis: therapeutic implications. N
Engl J Med 1971, 285:1182-1186.
48. Sander J, Schmidt SV, Cirovic B, McGovern N,
Papantonopoulou O, Hardt AL, Aschenbrenner AC, Kreer C,
Quast T, Xu AM et al.: Cellular differentiation of human
monocytes is regulated by time-dependent interleukin-4
signaling and the transcriptional regulator NCOR2. Immunity
2017, 47 1051–1066 e12.
49. Ginhoux F, Jung S: Monocytes and macrophages:
developmental pathways and tissue homeostasis. Nat Rev
Immunol 2014, 14:392-404.
50. Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB:
M-CSF induces vascular endothelial growth factor production
and angiogenic activity from human monocytes. J Immunol
2003, 171:2637-2643.
51. Hill LM, GavalaML, Lenertz LY, Bertics PJ:Extracellular ATPmay
contribute to tissue repair by rapidly stimulating purinergic
receptor X7-dependent vascular endothelial growth factor
release from primary human monocytes. J Immunol 2010,
185:3028-3034.
52. Poulin S, Thompson C, Thivierge M, Veronneau S, McMahon S,
Dubois CM, Stankova J, Rola-Pleszczynski M: Cysteinyl-
leukotrienes induce vascular endothelial growth factor
production in human monocytes and bronchial smooth
muscle cells. Clin Exp Allergy 2011, 41:204-217.
53. Czepluch FS, Olieslagers S, van Hulten R, Voo SA,Waltenberger J:
VEGF-A-induced chemotaxis of CD16+ monocytes is
decreased secondary to lower VEGFR-1 expression.
Atherosclerosis 2011, 215:331-338.
54.

De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS,
Sampaolesi M, Naldini L: Tie2 identifies a hematopoietic lineage
of proangiogenic monocytes required for tumor vessel
formation and a mesenchymal population of pericyte
progenitors. Cancer Cell 2005, 8:211-226.
This is the first identification of a hematopoietic lineage of proangiogenic
Tie2 monocytes required for tumor vessel formation.
55. Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N,
Miyazaki M, Sakakibara M, Hiramatsu N, Kasahara A et al.: TIE2-
expressing monocytes as a diagnostic marker for
hepatocellular carcinoma correlates with angiogenesis.
Hepatology 2013, 57:1416-1425.
56. Turrini R, Pabois A, Xenarios I, CoukosG, Delaloye JF, DouceyMA:
TIE-2 expressing monocytes in human cancers.
Oncoimmunology 2017, 6:e1303585.
57. Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A,
Plate KH, Reiss Y, Murdoch C, De Palma M, Lewis CE:www.sciencedirect.comAngiopoietin 2 stimulates TIE2-expressing monocytes to
suppress T cell activation and to promote regulatory T cell
expansion. J Immunol 2011, 186:4183-4190.
58. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS,
Gentner B, Brown JL, Naldini L, De Palma M: Targeting the
ANG2/TIE2 axis inhibits tumor growth and metastasis by
impairing angiogenesis and disabling rebounds of
proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
59. Bonavita E, Galdiero MR, Jaillon S, Mantovani A: Phagocytes as
corrupted policemen in cancer-related inflammation. Adv
Cancer Res 2015, 128:141-171.
60. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M:
Macrophage plasticity and polarization in tissue repair and
remodelling. J Pathol 2013, 229:176-185.
61. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A,
Jaillon S: Tumor associated macrophages and neutrophils in
cancer. Immunobiology 2013, 218:1402-1410.
62.

Staiano RI, Loffredo S, Borriello F, Iannotti FA, Piscitelli F,
Orlando P, Secondo A, Granata F, Lepore MT, Fiorelli A et al.:
Human lung-resident macrophages express CB1 and CB2
receptors whose activation inhibits the release of angiogenic
and lymphangiogenic factors. J Leukoc Biol 2016, 99:531-540.
This is the first demonstration that human lung macrophages express the
cannabinoid receptors and that their activation selectively inhibits the
release of angiogenic and lymphangiogenic factors.
63.

Gordon S, Pluddemann A: Tissue macrophages: heterogeneity
and functions. BMC Biol 2017, 15:53.
This review describes macrophage phenotypic heterogeneity in different
tissue environments, drawing particular attention to organ-specific
functions.
64.

Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases:
regulators of the tumor microenvironment. Cell 2010,
141:52-67.
This is a comprehensive review describing the role of matrix metallopro-
teinases as modulators of the tumor microenvironment.
65. Olson OC, Joyce JA: Cysteine cathepsin proteases: regulators
of cancer progression and therapeutic response. Nat Rev
Cancer 2015, 15:712-729.
66.

Varricchi G, Raap U, Rivellese F, Marone G, Gibbs B:Humanmast
cells and basophils—how are they similar, how are they
different? Immunol Rev 2018 http://dx.doi.org/10.1111/
imr.12627.
This comprehensive review illustrates the similarities and differences of
human mast cells and basophils and their distinct role in inflammatory
disorders and in cancer.
67. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF,
Claffey KP, Dvorak HF, Galli SJ:Mast cells can secrete vascular
permeability factor/vascular endothelial cell growth factor
and exhibit enhanced release after immunoglobulin E-
dependent upregulation of fc epsilon receptor I expression. J
Exp Med 1998, 188:1135-1145.
68. Abdel-Majid RM, Marshall JS: Prostaglandin E2 induces
degranulation-independent production of vascular
endothelial growth factor by human mast cells. J Immunol
2004, 172:1227-1236.
69. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M,
Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S,
Stavrianeas N et al.: IL-33 augments substance P-induced
VEGF secretion from human mast cells and is increased in
psoriatic skin. Proc Natl Acad Sci U S A 2010, 107:4448-4453.
70.

Wroblewski M, Bauer R, Cubas Cordova M, Udonta F, Ben-
Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J
et al.: Mast cells decrease efficacy of anti-angiogenic therapy
by secretingmatrix-degrading granzyme B.Nat Commun 2017,
8:269.
This report demonstrates that granzyme B, released by activated mast
cells, can decrease the efficacy of anti-angiogenic therapy.
71. De Monte L, Wormann S, Brunetto E, Heltai S, Magliacane G,
Reni M, Paganoni AM, Recalde H, Mondino A, Falconi M et al.:
Basophil recruitment into tumor-draining lymph nodes
correlates with Th2 inflammation and reduced survival in
pancreatic cancer patients. Cancer Res 2016, 76:1792-1803.Current Opinion in Immunology 2018, 53:152–160
160 Lymphangiogenesis: heterogeneity and function72. Prevete N, Rossi FW, Rivellese F, Lamacchia D, Pelosi C, Lobasso A,
Necchi V, Solcia E, Fiocca R, Ceppa P et al.:Helicobacter pyloriHP
(2-20) induces eosinophil activation and accumulation in
superficial gastricmucosa and stimulates VEGF-alpha and TGF-
beta release by interacting with formyl-peptide receptors. Int J
Immunopathol Pharmacol 2013, 26:647-662.
73. Galdiero MR, Bianchi P, Grizzi F, Di Caro G, Basso G, Ponzetta A,
Bonavita E, Barbagallo M, Tartari S, Polentarutti N et al.:
Occurrence and significance of tumor-associated neutrophils
in patients with colorectal cancer. Int J Cancer 2016,
139:446-456.
74.

Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L,
Worthen GS, Albelda SM: Polarization of tumor-associated
neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN.
Cancer Cell 2009, 16:183-194.
This is the first identification of neutrophils subpopulations (N1 vs N2) and
their different role in tumor growth.
75. Tecchio C, Micheletti A, Cassatella MA: Neutrophil-derived
cytokines: facts beyond expression. Front Immunol 2014, 5:508.
76. Triggiani M, Giannattasio G, Calabrese C, Loffredo S, Granata F,
Fiorello A, Santini M, Gelb MH, Marone G: Lung mast cells are a
source of secreted phospholipases A2. J Allergy Clin Immunol
2009, 124:558-565 565 e1–3.
77. Nozawa H, Chiu C, Hanahan D: Infiltrating neutrophils mediate
the initial angiogenic switch in a mouse model of multistage
carcinogenesis.ProcNatl Acad Sci U SA 2006, 103:12493-12498.
78.

Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G,
Mattei F, Marone G, Schiavoni G: Eosinophils: the unsung
heroes in cancer? OncoImmunology 2017 http://dx.doi.org/
10.1080/2162402X.2017.1393134.
This comprehensive review illustrates the complex roles of eosinophils
and their mediators in tumor initiation and progression.
79. Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F,
Buccione C, Sistigu A, Sanchez M, Andreone S, D’Urso MT et al.:
IL-33 restricts tumor growth and inhibits pulmonary
metastasis in melanoma-bearing mice through eosinophils.
Oncoimmunology 2017, 6:e1317420.
80. Horiuchi T, Weller PF: Expression of vascular endothelial
growth factor by human eosinophils: upregulation by
granulocyte macrophage colony-stimulating factor and
interleukin-5. Am J Respir Cell Mol Biol 1997, 17:70-77.
81.

Nissim Ben Efraim AH, Levi-Schaffer F: Roles of eosinophils in
the modulation of angiogenesis. Chem Immunol Allergy 2014,
99:138-154.
This elegant review describes the current understanding of the role of
human eosinophils in the modulation of angiogenesis.
82. Hoshino M, Takahashi M, Aoike N: Expression of vascular
endothelial growth factor, basic fibroblast growth factor, and
angiogenin immunoreactivity in asthmatic airways and its
relationship to angiogenesis. J Allergy Clin Immunol 2001,
107:295-301.Current Opinion in Immunology 2018, 53:152–16083. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P,
Hammerling GJ: Eosinophils orchestrate cancer rejection by
normalizing tumor vessels and enhancing infiltration of CD8(+)
T cells. Nat Immunol 2015, 16:609-617.
84. Yousefi S, Hemmann S, Weber M, Holzer C, Hartung K, Blaser K,
Simon HU: IL-8 is expressed by human peripheral blood
eosinophils. Evidence for increased secretion in asthma. J
Immunol 1995, 154:5481-5490.
85. Puxeddu I, Berkman N, Ribatti D, Bader R, Haitchi HM, Davies DE,
Howarth PH, Levi-Schaffer F: Osteopontin is expressed and
functional in human eosinophils. Allergy 2010, 65:168-174.
86. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R,
Mekori YA: Human mast cells release metalloproteinase-9 on
contact with activated T cells: juxtacrine regulation by TNF-
alpha. J Immunol 2001, 167:4008-4016.
87. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM:Migration
of eosinophils through basement membrane components in
vitro: role of matrix metalloproteinase-9. Am J Respir Cell Mol
Biol 1997, 17:519-528.
88. Schwingshackl A, Duszyk M, Brown N, Moqbel R: Human
eosinophils releasematrix metalloproteinase-9 on stimulation
with TNF-alpha. J Allergy Clin Immunol 1999, 104:983-989.
89.

Bry M, Kivela R, Holopainen T, Anisimov A, Tammela T, Soronen J,
Silvola J, Saraste A, Jeltsch M, Korpisalo P et al.: Vascular
endothelial growth factor-B acts as a coronary growth factor
in transgenic rats without inducing angiogenesis, vascular
leak, or inflammation. Circulation 2010, 122:1725-1733.
This review summarizes what is currently known about the main functions
of VEGF-B in physiology and disease.
90. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I,
van Meeteren LA, Samen E, Lu L, Vanwildemeersch M et al.:
Vascular endothelial growth factor B controls endothelial fatty
acid uptake. Nature 2010, 464:917-921.
91. Li X, Kumar A, Zhang F, Lee C, Tang Z: Complicated life,
complicated VEGF-B. Trends Mol Med 2012, 18:119-127.
92. Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M,
Ries CH, Ailles L, Jewett MAS, Moch H et al.: An immune atlas of
clear cell renal cell carcinoma. Cell 2017, 169 736–749 e18.
93.

Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J,
Manos MP, Lawrence D, McDermott D, Severgnini M et al.:
Angiopoietin-2 as a biomarker and target for immune
checkpoint therapy. Cancer Immunol Res 2017, 5:17-28.
This report suggests that angiopoietin-2 could be a predictive and
prognostic biomarker in metastatic melanoma patients receiving immune
checkpoint therapy.
94. Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T,
Sheng K, Dobrolecki LE, Zhang X, Putluri N et al.: Mutual
regulation of tumour vessel normalization and
immunostimulatory reprogramming.Nature 2017, 544:250-254.www.sciencedirect.com
